Sanofi Pasteur Enters Japanese Pediatric Vaccine Market
Posted on: Wednesday, 12 November 2008, 12:00 CST
Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, a French pharmaceutical group, has announced that it is the first international vaccine company to enter the Japanese pediatric vaccine market with ActHIB vaccine.
Sanofi Pasteur's ActHIB vaccine (Haemophilus influenzae type b conjugate vaccine) is marketed in Japan by Daiichi-Sankyo Co and will be available starting December 19, 2008.
Wayne Pisano, president and CEO of Sanofi Pasteur, said: "Sanofi Pasteur is proud to help protect Japanese children against bacterial meningitis and improve public health in the country. Being the first to enter the Japanese pediatric vaccine market is an achievement that underlines Sanofi Pasteur's strength and commitment to provide the highest quality innovative vaccines."
Source: Datamonitor
Related Articles
- Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for Its Influenza Vaccine Global Stockpile
- U.S. Government Accepts $192 Million of Sanofi Pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
- Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
- Sanofi Pasteur Signs Contract With U.S. Government for Stockpile of New Type of H5N1 Pre-Pandemic Vaccine
- Sanofi Pasteur Initiates Trials of First Cell Based Flu Vaccine
- Adjuvanted Formulation of Sanofi Pasteur H5N1 Pandemic Influenza Vaccine Candidate Demonstrates Significant Immune Response
- Sanofi Pasteur Delivers More H5N1 Vaccine for U.S. Government Pandemic Initiatives
- Sanofi Pasteur Announces Preliminary Trial Results for a First H5N1 Pre-Pandemic Influenza Vaccine Candidate With an Adjuvant
- Sanofi Pasteur to Increase U.S. Influenza Vaccine Capacity With Construction of New Plant
 |
 |
User Comments (0)
RSS Feeds